药物诱导性系统性红斑狼疮:基于WHO药物警戒数据库的疾病谱再审视
该研究利用WHO全球个体病例安全性报告数据库VigiBase,分析被归类为系统性红斑狼疮的个体病例安全性报告,筛选出IC025≥0且非用于治疗SLE的 suspected drugs。
要点
- DIL中位潜伏期约172天,临床需警惕长期用药后的迟发表现。
- 英夫利西单抗、阿达木单抗、依那西普、普鲁卡因胺和肼屈嗪报告例数最多。
- 42种药物为新发现与DIL相关的可疑药物,拓宽了致病药物谱。
核心结论
- 本研究识别出118种与药物诱导性狼疮相关的可疑药物,其中42种此前未报告与DIL相关。
研究设计与样本
- 基于WHO全球个体病例安全性报告数据库VigiBase,分析归类为系统性红斑狼疮的ICSRs,筛选非SLE治疗药物且IC025≥0者。
主要发现
- DIL发病中位年龄49岁,女性与男性性别比为4.3。
- 从可疑治疗开始至DIL发生的中位延迟为172天。
- DIL被报告为严重不良事件的比例为55.4%。
- 报告DIL病例数最多的药物为英夫利西单抗、阿达木单抗、依那西普、普鲁卡因胺和肼屈嗪。
关键数值与推荐
- 可疑药物需满足信息成分95%可信区间下限(IC025)≥0。
- DIL病例定义为VigiBase中按MedDRA首选术语归类为「系统性红斑狼疮」的ICSRs。
临床怎么用
- 临床医生面对疑似DIL病例时,可参考本研究的118种可疑药物列表进行用药史排查。
- 对使用英夫利西单抗、阿达木单抗、依那西普、普鲁卡因胺或肼屈嗪的患者,应关注DIL相关症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Drug-induced lupus (DIL) is an idiosyncratic side effect of treatments in which symptoms overlap with those of systemic lupus erythematosus (SLE). The spectrum of DIL constantly evolves with that of the pharmacopoeia. Here, we used VigiBase, the WHO global individual case safety reports (ICSRs) database, to identify the main drugs associated with DIL. METHODS: We analysed all ICSRs classified as 'systemic lupus erythematosus' according to the Medical Dictionary for Drug Regulatory Activities term (preferred term level) in VigiBase. The drugs considered in the analysis were those not used to treat SLE, with a positive lower end of the 95% credibility interval for the information component (IC025) ≥0, an indicator value for disproportionate Bayesian reporting. RESULTS: A total of 12 166 DIL ICSRs were identified using VigiBase. From those, 8163 ICSRs reporting on 118 suspected drugs with IC025 ≥0 were extracted. The median age at DIL onset was 49 years and the female to male sex ratio was 4.3. The median delay between start of suspected treatment and DIL occurrence was 172 days. DIL was reported as serious adverse event in 55.4%. Among the 118 suspected drugs, 42 had not been previously reported in association with DIL. The drugs associated with the highest number of DIL cases were infliximab, adalimumab, etanercept, procainamide and hydralazine. CONCLUSION: This study enables the identification of 118 drugs associated with DIL. The list of suspected drugs may prove useful to physicians when confronted with potential DIL cases. TRIAL REGISTRATION NUMBER: NCT03480529.
引用
- Arnaud L, Mertz P, Gavand PE, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019. PMID: 30793701. doi:10.1136/annrheumdis-2018-214598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。